Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolphe Thiebaut

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The Lancet. Infectious Diseases|November 20, 2020
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trialAndrew J Pollard, Odile Launay, Jean-Daniel Lelievre, et al.
Scientific Reports|May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteersYves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Epidemiology (Cambridge, Mass.)|November 26, 2015
A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation ModelFumiyo Nakagawa, Ard van Sighem, Rodolphe Thiebaut, et al.
Studies in Health Technology and Informatics|August 12, 2015
Proposal for a European Public Health Research Infrastructure for Sharing of health and Medical administrative data (PHRIMA)Anita Burgun, Dina V Oksen, Wolfgang Kuchinke, et al.
Lancet (London, England)|August 15, 2018
Prevention of Ebola virus disease through vaccination: where we are in 2018Yves Lévy, Clifford Lane, Peter Piot, et al.
Nature Immunology|August 23, 2024
Clonal succession after prolonged antiretroviral therapy rejuvenates CD8<sup>+</sup> T cell responses against HIV-1Eoghann White, Laura Papagno, Assia Samri, et al.
Nature Communications|April 3, 2026
Representation learning to advance multi-institutional studies with electronic health record data from US and FranceDoudou Zhou, Han Tong, Linshanshan Wang, et al.
PLOS Global Public Health|April 8, 2025
In danger: HIV vaccine research and development in EuropeRoger Tatoud, Yves Lévy, Roger Le Grand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 12, 2018
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral TherapyLuuk Gras, Margaret May, Lars Peter Ryder, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The Lancet. Infectious Diseases|November 20, 2020
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trialAndrew J Pollard, Odile Launay, Jean-Daniel Lelievre, et al.
Scientific Reports|May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteersYves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Epidemiology (Cambridge, Mass.)|November 26, 2015
A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation ModelFumiyo Nakagawa, Ard van Sighem, Rodolphe Thiebaut, et al.
Studies in Health Technology and Informatics|August 12, 2015
Proposal for a European Public Health Research Infrastructure for Sharing of health and Medical administrative data (PHRIMA)Anita Burgun, Dina V Oksen, Wolfgang Kuchinke, et al.
Lancet (London, England)|August 15, 2018
Prevention of Ebola virus disease through vaccination: where we are in 2018Yves Lévy, Clifford Lane, Peter Piot, et al.
Nature Immunology|August 23, 2024
Clonal succession after prolonged antiretroviral therapy rejuvenates CD8<sup>+</sup> T cell responses against HIV-1Eoghann White, Laura Papagno, Assia Samri, et al.
Nature Communications|April 3, 2026
Representation learning to advance multi-institutional studies with electronic health record data from US and FranceDoudou Zhou, Han Tong, Linshanshan Wang, et al.
PLOS Global Public Health|April 8, 2025
In danger: HIV vaccine research and development in EuropeRoger Tatoud, Yves Lévy, Roger Le Grand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 12, 2018
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral TherapyLuuk Gras, Margaret May, Lars Peter Ryder, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
Pageof 6